FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376604833> ?p ?o ?g. }

• W4376604833 endingPage "323" @default.
• W4376604833 startingPage "315" @default.
• W4376604833 abstract "Background Patients undergoing surgical procedures are at an increased risk of venous thromboembolism events. A fixed Enoxaparin dosing regimen is the standard of care for chemoprophylaxis in most institutions; however, breakthrough venous thromboembolism events are still reported. We aimed to systematically review the literature to determine the ability of various Enoxaparin dosing regimens to achieve adequate prophylactic anti-Xa levels for venous thromboembolism prevention in hospitalized general surgery patients. Additionally, we aimed to assess the correlation between subprophylactic anti-Xa levels and the development of clinically significant venous thromboembolism events. Methods A systematic review was conducted using major databases from January 1, 1993, to February 17, 2023. Two independent researchers screened titles and abstracts, followed by a full-text review. Articles were included if Enoxaparin dosing regimens were evaluated by anti-Xa levels. Exclusion criteria included systematic reviews, pediatric population, nongeneral surgery (defined as trauma, orthopedics, plastics, and neurosurgery), and non-Enoxaparin chemoprophylaxis. The primary outcome was peak Anti-Xa level measured at steady state concentration. The risk of bias was assessed using the Risk of Bias in Nonrandomized studies-of Intervention tool. Results A total of 6,760 articles were extracted, of which 19 were included in the scoping review. Nine studies included bariatric patients, whereas 5 studies explored abdominal surgical oncology patients. Three studies assessed thoracic surgery patients, and 2 studies included patients undergoing “general surgery” procedures. A total of 1,502 patients were included. The mean age was 47 years, and 38% were males. The percentages of patients reaching adequate prophylactic anti-Xa levels were 39%, 61%, 15%, 50%, and 78% across the 40 mg daily, 40 mg twice daily, 30 mg twice daily, and weight-tiered, and body mass index-based groups, respectively. The overall risk of bias was low to moderate. Conclusion Fixed Enoxaparin dosing regimens are not correlated with adequate anti-Xa levels in general surgery patients. Additional research is warranted to assess the efficacy of dosing regimens based on novel physiologic parameters (such as estimated blood volume)." @default.
• W4376604833 created "2023-05-17" @default.
• W4376604833 creator A5001969109 @default.
• W4376604833 creator A5007123234 @default.
• W4376604833 creator A5010272882 @default.
• W4376604833 creator A5051465004 @default.
• W4376604833 creator A5054138509 @default.
• W4376604833 creator A5060355695 @default.
• W4376604833 creator A5077941273 @default.
• W4376604833 creator A5088687661 @default.
• W4376604833 date "2023-08-01" @default.
• W4376604833 modified "2023-10-17" @default.
• W4376604833 title "The efficacy of various Enoxaparin dosing regimens in general surgery patients: A systematic review" @default.
• W4376604833 cites W1964233296 @default.
• W4376604833 cites W1964926308 @default.
• W4376604833 cites W1972498313 @default.
• W4376604833 cites W1974849536 @default.
• W4376604833 cites W1989644527 @default.
• W4376604833 cites W2024066122 @default.
• W4376604833 cites W2032668280 @default.
• W4376604833 cites W2036257425 @default.
• W4376604833 cites W2084295055 @default.
• W4376604833 cites W2090543722 @default.
• W4376604833 cites W2097567723 @default.
• W4376604833 cites W2132905873 @default.
• W4376604833 cites W2142041696 @default.
• W4376604833 cites W2223301903 @default.
• W4376604833 cites W2322068631 @default.
• W4376604833 cites W2353286098 @default.
• W4376604833 cites W2396028391 @default.
• W4376604833 cites W2507903467 @default.
• W4376604833 cites W2523397505 @default.
• W4376604833 cites W2531269403 @default.
• W4376604833 cites W2600204735 @default.
• W4376604833 cites W2704279793 @default.
• W4376604833 cites W2736053603 @default.
• W4376604833 cites W2739559006 @default.
• W4376604833 cites W2758567736 @default.
• W4376604833 cites W2790760874 @default.
• W4376604833 cites W2794627957 @default.
• W4376604833 cites W2796165711 @default.
• W4376604833 cites W2801678602 @default.
• W4376604833 cites W2944967372 @default.
• W4376604833 cites W2952859337 @default.
• W4376604833 cites W2955693633 @default.
• W4376604833 cites W2996226968 @default.
• W4376604833 cites W3004630456 @default.
• W4376604833 cites W3022482992 @default.
• W4376604833 cites W3036837413 @default.
• W4376604833 cites W3081400901 @default.
• W4376604833 cites W3143751880 @default.
• W4376604833 cites W3163094039 @default.
• W4376604833 cites W3164383896 @default.
• W4376604833 cites W4205814956 @default.
• W4376604833 cites W4210762282 @default.
• W4376604833 cites W4226102495 @default.
• W4376604833 cites W4280506168 @default.
• W4376604833 cites W4288914022 @default.
• W4376604833 doi "https://doi.org/10.1016/j.surg.2023.04.032" @default.
• W4376604833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37198037" @default.
• W4376604833 hasPublicationYear "2023" @default.
• W4376604833 type Work @default.
• W4376604833 citedByCount "0" @default.
• W4376604833 crossrefType "journal-article" @default.
• W4376604833 hasAuthorship W4376604833A5001969109 @default.
• W4376604833 hasAuthorship W4376604833A5007123234 @default.
• W4376604833 hasAuthorship W4376604833A5010272882 @default.
• W4376604833 hasAuthorship W4376604833A5051465004 @default.
• W4376604833 hasAuthorship W4376604833A5054138509 @default.
• W4376604833 hasAuthorship W4376604833A5060355695 @default.
• W4376604833 hasAuthorship W4376604833A5077941273 @default.
• W4376604833 hasAuthorship W4376604833A5088687661 @default.
• W4376604833 hasConcept C126322002 @default.
• W4376604833 hasConcept C141071460 @default.
• W4376604833 hasConcept C2776688490 @default.
• W4376604833 hasConcept C2777288759 @default.
• W4376604833 hasConcept C2780868729 @default.
• W4376604833 hasConcept C2781413609 @default.
• W4376604833 hasConcept C2908647359 @default.
• W4376604833 hasConcept C2991741193 @default.
• W4376604833 hasConcept C68312169 @default.
• W4376604833 hasConcept C71924100 @default.
• W4376604833 hasConcept C99454951 @default.
• W4376604833 hasConceptScore W4376604833C126322002 @default.
• W4376604833 hasConceptScore W4376604833C141071460 @default.
• W4376604833 hasConceptScore W4376604833C2776688490 @default.
• W4376604833 hasConceptScore W4376604833C2777288759 @default.
• W4376604833 hasConceptScore W4376604833C2780868729 @default.
• W4376604833 hasConceptScore W4376604833C2781413609 @default.
• W4376604833 hasConceptScore W4376604833C2908647359 @default.
• W4376604833 hasConceptScore W4376604833C2991741193 @default.
• W4376604833 hasConceptScore W4376604833C68312169 @default.
• W4376604833 hasConceptScore W4376604833C71924100 @default.
• W4376604833 hasConceptScore W4376604833C99454951 @default.
• W4376604833 hasIssue "2" @default.
• W4376604833 hasLocation W43766048331 @default.
• W4376604833 hasLocation W43766048332 @default.
• W4376604833 hasOpenAccess W4376604833 @default.

• next